newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights

MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in